Based on data from the BEACON and NAUTICAL studies, regulatory authorities greenlit the combo for later-line patients.

ARPA-H, part of HHS, has earmarked up to $142 million for 10 research projects building the tools, data, and infrastructure needed to tackle treatment resistance.